Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis.

Published in: Therapeutic advances in medical oncology (2023)

From the perspective of the United States healthcare system, the utilization of cemiplimab in combination with chemotherapy as a first-line treatment option for NSCLC appears to be a cost-effective approach as compared to using chemotherapy as a standalone therapy.

Keyphrases

advanced non small cell lung cancer
locally advanced
epidermal growth factor receptor
small cell lung cancer
clinical trial
squamous cell carcinoma
stem cells
study protocol
radiation therapy
randomized controlled trial
phase iii
mesenchymal stem cells